Hormone therapy: Improving therapy decisions and monitoring

European Urology, Supplements

Volumn 5, Issue 3 SPEC. ISS., 2006, Pages 369-376

  Zlotta, Alexandre R ^a   Abrahamsson, Per Anders ^b   Tombal, Bertrand ^c   Berges, Richard ^d   Debruyne, Frans ^e  

^a ERASME HOSPITAL   (Belgium)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d PAN Klinik am Neumarkt   (Germany)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EAU guidelines; LHRH agonists; Monitoring; Prostate cancer; Prostate specific antigen; Testosterone; Treatment decision

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; ESTROGEN; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; NILUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULARY; DRUG MECHANISM; FOLLOW UP; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MASTALGIA; MEDLINE; META ANALYSIS; NAUSEA; ORCHIECTOMY; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE; VOMITING;

EID: 33644747286     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.01.002     Document Type: Article

References (55)

1. M.R. Cooperberg, D.P. Lubeck, M.V. Meng, S.S. Mehta, and P.R. Carroll The changing face of low-risk prostate cancer: trends in clinical presentation and primary management J Clin Oncol 22 2004 2141 2149
2. P.A. Abrahamsson, J. Anderson, L. Boccon-Gibod, C. Schulman, U.E. Studer, and M. Wirth Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer Eur Urol 48 2005 900 905
3. A.V. D'Amico, J.W. Moul, P.R. Carroll, L. Sun, D. Lubkeck, and M.H. Chen Surrogate end point for prostate cancer specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
4. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
5. J.F. Ward, M.L. Blute, J. Slezak, E.J. Bergstralh, and H. Zincke The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 170 2003 1872 1876
6. J.W. Moul, H. Wu, and L. Sun Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2004 1141 1147
7. G. Aus, C.C. Abbou, and M. Bolla EAU guidelines on prostate cancer Eur Urol 48 2005 546 551
8. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Updated full version, http://www.uroweb.org, March 2005.
9. U.E. Studer, D. Hauri, and S. Hanselmann Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88 J Clin Oncol 22 2004 4109 4118
10. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
11. L. Boccon-Gibod Optimising hormone therapy in advanced disease Eur Urol Suppl 4 2005 21 29
12. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
13. C. Huggins, R.E. Stevens Jr., and C.V. Hodges Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland Arch Surg 43 1941 209 223
14. B.R. Cassileth, M.S. Soloway, and N.J. Vogelzang Patients' choice of treatment in stage D prostate cancer Urology 33 5 suppl 1989 57 62
15. D.P. Byar, and D.K. Corle Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies NCI Monogr 1988 165 170
16. D. McLeod, N. Zinner, and K. Tomera A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer Urology 58 2001 756 761
17. P. Iversen, J.E. Johansson, and P. Lodding Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6 J Urol 172 2004 1871 1876
18. J. Anderson The role of antiandrogen monotherapy in the treatment of prostate cancer BJU Int 91 2003 455 461
19. Prostate Cancer Triallists 'Collaborative Group' Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 335 2000 1491 1498
20. D.J. Samson, J. Seidenfeld, and B. Schmitt Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2002 361 376
21. M.P. Wirth, W.A. See, and D.G. McLeod Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years J Urol 172 2004 1865 1870
22. C.J. Tyrrell, A.V. Kaisary, P. Iversen, J.B. Anderson, L. Baert, and T. Tammela A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer Eur Urol 33 1998 447 456
23. F.H. Schroder, P. Whelan, and T.M. de Reijke Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892 Eur Urol 45 2004 457 464
24. S.C. Thorpe, S. Azmatullah, G.J. Fellows, J.C. Gingell, and P.J. O'Boyle A prospective, randomised study to compare gosereline acetate (Zoladex) versus cyproterone acetate (Cyprostat) versus a combination of the two in the treatment of metastatic prostatic carcinoma Eur Urol 29 1996 47 54
25. E. Jacobo, J.D. Schmidt, S.H. Weinstein, and R.H. Flocks Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer Urology 8 1976 231 233
26. F. Lund, and F. Rasmussen Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study Br J Urol 61 1988 140 142
27. J. Seidenfeld, D.J. Samson, and V. Hasselblad Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 2000 566 577
28. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
29. A.V. Kaisary, C.J. Tyrrell, W.B. Peeling, and K. Griffiths Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma Br J Urol 67 1991 502 508
30. H.F. Rohl, and H.P. Beuke Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer Scand J Urol Nephrol 26 1992 11 14
31. B.J. Lin, K.K. Chen, M.T. Chen, and L.S. Chang The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer Urology 43 1994 834 837
32. N.J. Vogelzang, G.W. Chodak, and M.S. Soloway Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group Urology 46 1995 220 226
33. A. Zlotta, and F. Debruyne Expert consultation on optimal testosterone control in prostate cancer Eur Urol Suppl 4 2005 37 41
34. M.G. Oefelein, and R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 2000 726 729
35. Morote J, Esquena S, Abascal JM, et al. In press.
36. S. Esquena, J.M. Abascal, E. Trilla, and J. Morote Failure of luteinising hormonal releasing hormonal agonist therapy to achieve castration. Does it exist? Eur Urol Suppl 3 2004 57 (abstract no. 218)
37. H.W. Wechsel, M. Zerbib, F. Pagano, and M.J. Coptcoat Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer Eur Urol 30 suppl 1 1996 7 14
38. J. Kawakami, and A. Morales A comprehensive hormonal evaluation in patients with cancer of the prostate on androgen suppression with LHRH agonists J Urol 167 suppl 4 2002 288
39. U.W. Tunn, U. Bargelloni, S. Cosciani, G. Fiaccavento, S. Guazzieri, and F. Pagano Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer Urol Int 60 suppl 1 1998 9 16
40. M.F. Sarosdy, P.F. Schellhammer, and M.S. Soloway Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer BJU Int 83 1999 801 806
41. N.R. Zinner, M. Bidair, A. Centeno, and K. Tomera Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial Urology 64 2004 1177 1181
42. R. Sharifi, and R. Browneller Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer J Urol 168 2002 1001 1004
43. D. Fontana, M. Mari, and A. Martinelli 3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial Urol Int 70 2003 316 320
44. D. Jocham Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results Urol Int 60 suppl 2 1998 18 24
45. M.S. Khan, and A. O'Brien An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate Urol Int 60 1998 33 40
46. R. Perez-Marreno, F.M. Chu, D. Gleason, E. Loizides, B. Wachs, and R.C. Tyler A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer Clin Ther 24 2002 1902 1914
47. F.M. Chu, M. Jayson, M.K. Dineen, R. Perez, R. Harkaway, and R.C. Tyler A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer J Urol 168 2002 1199 1203
48. R. Perez-Marrero, and R.C. Tyler A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer Expert Opin Pharmacother 5 2004 447 457
49. O. Sartor Eligard: leuprolide acetate in a novel sustained-release delivery system Urology 61 2 suppl 1 2003 25 31
50. A. Dupont, L. Cusan, J.L. Gomez, M.M. Thibealut, M. Tremblay, and F. Labrie Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate J Urol 146 1991 1064 1067
51. S.D. Fossa, H. Waehre, and E. Paus The prognostic significance of prostate cancer Br J Cancer 66 1992 181 184
52. A.V. Schally, A.J. Kastin, and A. Arimura Hypothalamic follicle-stimulating hormone (FSH) and luteinizing hormone (LH)-regulating hormone: structure, physiology, and clinical studies Fertil Steril 22 1971 703 721
53. D.H. Coy, J.A. Vilchez-Martinez, E.J. Coy, A. Arimura, and A.V. Schally A peptide inhibitor of luteinizing hormone-releasing hormone (LH-RH) J Clin Endocrinol Metab 37 1973 331 333
54. T.J. Wilke, and D.J. Utley Total testosterone, free-androgen index, calculated free testosterone, and free testosterone by analog RIA compared in hirsute women and in otherwise-normal women with altered binding of sex-hormone-binding globulin Clin Chem 33 1987 1372 1375
55. M.A. Hoffman, W.C. DeWolf, and A. Morgentaler Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 2000 824 827